Ugandan Pharmaceutical Company to Invest $80 Million for Expansion; Some Funds Will Go to Generic AIDS, Malaria Drug Plants
February 2, 2011
"Quality Chemicals Industries Ltd., a Ugandan pharmaceuticals manufacturer partly owned by India's Cipla Ltd., said it plans to invest $80 million in two separate expansion programs over the next two years," Bloomberg Businessweek reports. According to the news service, $30 million of the funds will be used to expand the capacity of the company's generic AIDS and malaria-drug plants, and $50 million will be put towards "a new production line for pharmaceutical ingredients." Bloomberg notes that "Quality Chemicals' plant in [the Ugandan capital city] Kampala has the capacity to produce 6 million malaria or generic AIDS tablets daily, with room for expansion, according to the company." The piece notes the numbers of patients living with HIV/AIDS and malaria in Uganda as well as neighboring countries who could benefit from access to generic medications (Ojambo, 2/1).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)